Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NDMC101 是有效的破骨细胞形成抑制剂,通过下调 NFATc1 调控基因表达抑制破骨细胞分化。它与 DPP4底物相似,通过抑制DPP4抑制早期 T 细胞激活。它能够用于骨疾病的研究,如类风湿关节炎、滑膜炎等。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 248 | 现货 | ||
2 mg | ¥ 355 | 现货 | ||
5 mg | ¥ 578 | 现货 | ||
10 mg | ¥ 980 | 现货 | ||
25 mg | ¥ 1,930 | 现货 | ||
50 mg | ¥ 3,320 | 现货 | ||
100 mg | ¥ 4,880 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 555 | 现货 |
产品描述 | NDMC101 is an inhibitor of dipeptidyl peptidase-IV activity in human T cells and exhibits immunomodulatory effects. It also acts as a novel inhibitor of NFATc1 and NF-κB activity. |
体外活性 | NDMC101 markedly inhibited RANKL-induced formation of TRAP+ multinucleated cells in RAW264.7 and bone marrow macrophage cells (BMMs).?Moreover, pit formation assay showed that NDMC101 significantly reduced the bone-resorbing activity of mature osteoclasts[1]. |
体内活性 | In CIA mice, oral administration of NDMC101 reduced arthritic index and mitigated bone erosion.?Serum TNF-α and IL-1β concentrations in these mice were decreased significantly at the higher dose of 62.5 mg/kg[1]. |
细胞实验 | Differentiation into osteoclast-like cells was examined by tartrate-resistant acid phosphatase (TRAP) staining and expression of osteoclast differentiation markers[1]. |
动物实验 | Collagen-induced arthritis (CIA) mice were administered test articles by gavages to assess its efficacy.?Then clinical, histological, and biochemical parameters were assessed to determine the effects of N-(4-chloro-2-fluorophenyl)-2-hydroxybenzamide (NDMC101) on synovial inflammation and bone erosion by hematoxlin and eosin staining and Enzyme-linked immunosorbent assay (ELISA)[1]. |
分子量 | 265.67 |
分子式 | C13H9ClFNO2 |
CAS No. | 1308631-40-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11 mg/mL (41.4 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.7641 mL | 18.8203 mL | 37.6407 mL | 94.1017 mL |
5 mM | 0.7528 mL | 3.7641 mL | 7.5281 mL | 18.8203 mL | |
10 mM | 0.3764 mL | 1.882 mL | 3.7641 mL | 9.4102 mL | |
20 mM | 0.1882 mL | 0.941 mL | 1.882 mL | 4.7051 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NDMC101 1308631-40-4 NF-Κb Others Proteases/Proteasome Ubiquitination NF-κB Proteasome rheumatoid arthritis inhibit RAW 264.7 NDMC-101 NSAID NDMC 101 Bone Inhibitor Nuclear factor-κB DPP bone destruction osteoblast marrow-derived macrophages synovial inflammation Nuclear factor-kappaB Dipeptidyl Peptidase inhibitor